Cabaletta’s CAAR Ts for autoimmunity

How Cabaletta is treating B cell-mediated autoimmunity without wiping out all B cells

Cabaletta Bio Inc.’s CAAR T therapy is geared to treat B cell-mediated autoimmunity without wiping out all B cells. The company is betting an antigen-specific approach will yield efficacy without CARs’ safety drawbacks.

Cabaletta spun out of University of Pennsylvania in 2017 with exclusive global rights to the autoimmune applications of the university’s CAR T technology. Its chimeric autoantibody receptor (CAAR)-mediated cell therapies are autologous

Read the full 642 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE